← Browse by Condition
Medical Condition

oligometastasis

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 3

ClinicalMetric tracks all active clinical trials for oligometastasis sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — oligometastasis Clinical Trials

How many clinical trials are currently recruiting for oligometastasis?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for oligometastasis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for oligometastasis?
oligometastasis research spans Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a oligometastasis clinical trial?
Eligibility criteria for oligometastasis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 3
2
Top Sponsors
Tokyo Medical and Dental University 1 trial
Istituto Clinico Humanitas 1 trial
Sun Yat-sen University 1 trial
Universitaire Ziekenhuizen KU Leuven 1 trial

Recruiting Clinical Trials

NCT06135714 Phase 3
Recruiting

Metastasis-directed Therapy for Oligometastases of Breast Cancer

Enrollment
340 pts
Location
Japan
Sponsor
Tokyo Medical and Dental Unive...
View Trial →
NCT07397585
Recruiting

stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective Database

Enrollment
300 pts
Location
Italy
Sponsor
Istituto Clinico Humanitas
View Trial →
NCT06550921
Recruiting

Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

Enrollment
60 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT05352178 Phase 3
Recruiting

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

Enrollment
873 pts
Location
Belgium
Sponsor
Universitaire Ziekenhuizen KU ...
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology